Want to see AU:BLS full AI Analyst Report?
BLS Stock Chart & Stats
AU$0.04
<AU$0.01(4.17%)
At close: 4:00 PM EST
AU$0.04
<AU$0.01(4.17%)
Day’s Range― - ―
52-Week RangeAU$0.33 - AU$1.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.35M
Market Cap
AU$185.57M
Enterprise ValueAU$228.67M
Total Cash (Recent Filing)AU$7.60M
Total Debt (Recent Filing)AU$7.43M
Price to Earnings (P/E)23.1
Beta1.52
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding229,103,590
10 Day Avg. Volume2,483,521
30 Day Avg. Volume4,348,514
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)7.54
Price to Sales (P/S)2.90
P/FCF Ratio22.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)AU$105.60M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained high revenue growth indicates strong product uptake and expanding market penetration in regulated medicinal cannabis channels. Over 2-6 months this underpins reinvestment ability, supports scale economics, and helps justify further commercialization and regulatory investment to extend market access.
Robust Cash GenerationA dramatic improvement in free cash flow and solid cash conversion ratios provides durable funding for capex, inventory, and regulatory compliance without reliance on frequent external financing. Strong cash conversion also increases resilience to margin pressure and supports measured expansion into new regulated markets.
Conservative Leverage, High ROELow leverage combined with very high ROE signals efficient capital use and financial flexibility. This structural strength allows the company to fund growth initiatives, absorb regulatory or cycle shocks, and invest in production or distribution capacity without materially increasing financial risk.
Bears Say
Relatively Low Gross MarginA sub-40% gross margin constrains the company's ability to absorb input cost inflation and invest in R&D or market expansion while maintaining healthy net margins. Over several months this limits margin sustainability versus peers and necessitates operational or procurement improvements to improve long-term profitability.
Regulatory And Licence DependenceHeavy reliance on regulated markets and licences is a structural business risk: regulatory changes, approval delays or tighter controls can materially restrict sales or delay market entry. This creates persistent execution risk and can lengthen timelines for scaling revenue in new jurisdictions.
Limited Operational ScaleA very small headcount suggests constrained internal capacity for large-scale cultivation, quality control, and broader commercialization. Sustained growth will require hiring, systems and partner reliance; scaling execution risk and capacity bottlenecks could limit consistent supply and market expansion over the medium term.
Bioxyne Limited News
BLS FAQ
What was Bioxyne Limited’s price range in the past 12 months?
Bioxyne Limited lowest share price was AU$0.33 and its highest was AU$1.10 in the past 12 months.
What is Bioxyne Limited’s market cap?
Bioxyne Limited’s market cap is AU$185.57M.
When is Bioxyne Limited’s upcoming earnings report date?
Bioxyne Limited’s upcoming earnings report date is Aug 28, 2026 which is in 22 days.
How were Bioxyne Limited’s earnings last quarter?
Bioxyne Limited released its earnings results on Feb 25, 2026. The company reported AU$0.033 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.033.
Is Bioxyne Limited overvalued?
According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued.
Does Bioxyne Limited pay dividends?
Bioxyne Limited does not currently pay dividends.
What is Bioxyne Limited’s EPS estimate?
Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioxyne Limited have?
Bioxyne Limited has 229,103,590 shares outstanding.
What happened to Bioxyne Limited’s price movement after its last earnings report?
Bioxyne Limited reported an EPS of AU$0.033 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.192%.
Which hedge fund is a major shareholder of Bioxyne Limited?
Currently, no hedge funds are holding shares in AU:BLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioxyne Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
131.94%
Trailing 12-Months
Company Description
Bioxyne Limited
BLS Pharmaceuticals Ltd. engages in the research, development, market and distribution of health products. It operates through the following segments: Wholesale, Plant Based, and Direct Sales. The Wholesale segment covers operation in United States of America (USA), and Asia. The Plant Based segment includes manufacturing, commercialization, and distribution of plant-based products. The Direct Sales segment focuses on Australia, and Asia operation. The company was founded in 1998 and is headquartered in Sydney, Australia.
Technical Analysis
Bubs Australia Ltd.
―
Nuchev Pty Ltd
―
Holista Colltech Limited
―
Nutritional Growth Solutions Ltd.
―
Clover Corporation Limited
―